The debate identified elevated CSF SV2A in AD but could not resolve whether glycosylation defects drive hyperexcitability or are downstream consequences. This causal direction determines whether SV2A glycosylation is a therapeutic target or biomarker. Source: Debate session sess_SDA-2026-04-16-gap-debate-20260411-065018-92a34465_20260416-134725 (Analysis: SDA-2026-04-16-gap-debate-20260411-065018-92a34465)
0
investigations
0
debates
debate:sess_SDA-2026-04-16-gap-debate-20260411-065018-92a34465_20260416-134725
source
Scores
Composite
0.694
Importance
0.820
Tractability
0.750
Novelty
0.800
Priority
0.850
Market Price
0.500